Dataset Information

Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography-Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors.

ABSTRACT:

Objectives

A prospective clinical trial evaluated the effect of Ga-DOTATOC positron emission tomography-computerized axial tomography (PET-CT) on change in management of patients with lung, pancreatic, and small bowel neuroendocrine tumors. The primary eligibility criterion was a histologically proven tumor with positive somatostatin receptor subtype 2A immunohistochemistry. The primary and secondary end points were change in patient management and safety.

Methods

Referring physicians completed questionnaires pre- and post-Ga-DOTATOC PET-CT, stating current and planned patient management, respectively, with tumor board adjudication of final management decisions. Change in management was categorized as follows: no change; minor change (additional imaging, supportive care); or major change (octreotide/lanreotide therapy, tumor biopsy, surgery, peptide receptor radiotherapy, chemotherapy, biological therapy, liver embolization).

Results

A major change in management was recommended for 54 (47.37%) of 114 subjects and a minor change for 6 (5.26%) of 114 subjects, with no change for 54 (47.37%) of 114 subjects. Grade 1 adverse events were observed in 26 of 114 subjects (nausea, headache, back pain, diarrhea); one grade 2 (petechiae) and one grade 3 (abdominal pain) adverse event were observed. No grade 2 or 3 adverse events were related to study drug and none required intervention.

Conclusions

Imaging with Ga-DOTATOC PET-CT has a significant impact on management of patients with neuroendocrine tumors.

SUBMITTER: Ghobrial SN

PROVIDER: S-EPMC7447173 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography-Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors.

Ghobrial Silvia N SN Menda Yusuf Y Zamba Gideon K GK Mott Sarah L SL Gaimari-Varner Kristin K Dick David D Dillon Joseph J Howe James R JR Graham Michael M Sunderland John J Bellizzi Andrew A O'Dorisio Thomas M TM O'Dorisio M Sue MS

Pancreas 20200901 8

<h4>Objectives</h4>A prospective clinical trial evaluated the effect of Ga-DOTATOC positron emission tomography-computerized axial tomography (PET-CT) on change in management of patients with lung, pancreatic, and small bowel neuroendocrine tumors. The primary eligibility criterion was a histologically proven tumor with positive somatostatin receptor subtype 2A immunohistochemistry. The primary and secondary end points were change in patient management and safety.<h4>Methods</h4>Referring physic ...[more]

PMID: 32769854

Similar Datasets

Project description:Malignant melanoma tends to aggressively metastasize, resulting in it being a potentially lethal form of skin cancer with high mortality rates. The advanced stages of melanoma have a very poor prognosis because of the high tendency for metastasis, and there is therefore, a strong desire to develop efficient technology for the early detection of melanoma. The benzamide structure, which contains aromatic ring and amine group, exhibits a high affinity for melanin, making it a promising agent for targeting melanoma in diagnostic and therapeutic applications. In this study, we synthesized a fluorinated benzamide derivative and chelated it with the radioisotope 68Ga to detect melanoma on positron emission tomography (PET) imaging, and then evaluated its biological properties. We synthesized the new probe 2,2',2,"2"'-(2-(4-(3-(2-((2-(5-fluoropicolinamido)ethyl)(methyl)amino)ethyl)thioureido)benzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (MI-0202C1) for melanoma imaging from 5-fluoropyridine-2-carboxylic acid and conjugated 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for chelation with 68Ga. The radiochemical yield and radiochemical purity of the 68Ga chelation complex were confirmed by radio-thin layer chromatography (radio TLC). In vitro cellular uptake of 68Ga-MI-0202C1 was verified in B16F10 cells (murine melanoma). In vivo distribution and small animal PET studies were conducted on mice bearing B16F10 xenografts. The MI-0202C1 was chelated with 68Ga at 90°C for 10 min at pH 5, resulting in a radiochemical yield and radiochemical purity of over 95%. The cellular uptake of 68Ga-MI-0202C1 over 60 min was higher in a group treated with L-tyrosine (2 mM) than in a non-treated group, indicating selective uptake of melanin. 68Ga-MI-0202C1 successfully visualized B16F10 xenografts in microPET imaging performed at 30 and 60 min after intravenous injection, suggesting that 68Ga-MI-0202C1 has considerable potential as a diagnostic probe for melanoma.

Dataset Information

Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography-Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors.

Objectives

Methods

Results

Conclusions

Publications

Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography-Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets